Wayne A. Solley, M.D. Curriculum Vitae

Size: px

Start display at page:

Download "Wayne A. Solley, M.D. Curriculum Vitae"

Jean Mitchell
6 years ago
Views:

1 Wayne A. Solley, M.D. Curriculum Vitae Work Texas Retina Associates 801 W. Randol Mill Road, Suite 101 Arlington, Texas Telephone Fax BIOGRAPHICAL DATA Date of Birth Place of Birth Muscatine, Iowa Marital Status Married PRACTICE EXPERIENCE 8/1999 present Texas Retina Associates Arlington, Texas HOSPITAL STAFF APPOINTMENTS 8/1999 present Arlington Memorial Hospital Arlington, Texas 8/1999 present Presbyterian Hospital Dallas, Texas 2000 present Baylor Medical Center Grapevine, Texas POST GRADUATE EDUCATION 7/1997 6/1999 Fellow, Vitreoretinal Disease and Surgery Emory Eye Center, Atlanta, Georgia Chairman: Thomas Aaberg, Sr., M.D. 7/1996 6/1997 Chief Resident, Ophthalmology Emory Eye Center, Atlanta, Georgia Chairman: Thomas Aaberg, Sr., M.D. 7/1994 6/1997 Resident, Ophthalmology Emory Eye Center, Atlanta, Georgia Chairman: Thomas Aaberg, Sr., M.D. 7/1993 6/1994 Transitional Internship The Baptist Medical Centers, Birmingham, Alabama Chairman: Joe Bancroft, M.D.

2 EDUCATION 8/1989 5/1993 University of Iowa College of Medicine M.D. conferred May 1993, with Honors Iowa City, Iowa 8/1985 5/1989 Louisiana Tech University B.S., Zoology, conferred May 1989, summa cum laude HONORS AND AWARDS Chief Resident in Ophthalmology, Alpha Omega Alpha Junior Year Inductee, 1992; Treasurer, Gross Human Anatomy Prosector, 1990 Mortar Board, President, 1989 Omicron Delta Kappa Honor Society, 1989 Outstanding Entering Zoology Student Award, 1985 Outstanding Freshman Zoology Student Award, 1986 Monsanto Corporation National Merit Scholarship, Virginia Cage Memorial Award, 1989 CERTIFICATION AND LICENSURE Diplomate, American Board of Ophthalmology, May 16, 1999 Texas licensure, April 10, 1999 to present (License # K7398) PROFESSIONAL ASSOCIATIONS American Academy of Ophthalmology American Medical Association Alpha Omega Alpha Vitreous Society PRESENTATIONS Posterior Segment Manifestations of Cat Scratch Disease ; Residents Day, June 5, 1996, Atlanta, Georgia Telemedicine Diabetic Eye Screening in Urban African-American Population ; Residents Day, June 7, 1997, Atlanta, Georgia Solley W A, Martin D, Newman N, et al. Cat Scratch Disease: Posterior Segment Manifestations ; Poster presented at American Academy of Ophthalmology Annual Meeting, San Francisco, California, October 1997

3 PUBLICATIONS Segal W A, Solley W A, Sternberg P S, Capone A C. Refractive Outcome Following Unilateral Retinopexy in Infants with Asymmetric Retinopathy of Prematurity. Progress in Retinopathy of Prematurity, pp , Kugler Publications, 1997 (Proceedings of the International Symposium of Prematurity, Taormna, Italy, September 21 24, 1997) Solley W A, Martin D, Newman N, et al. Cat Scratch Disease: Posterior Segment Manifestations. Ophthalmology 1999, 106: Solley W A, Broocker G. The General Eye Exam. In: Ophthalmology for the Primary Care Physician; Palay D A, Krachmer J H, eds.: Mosby 1997 Solley W A, Broocker G. Ocular Trauma. In: Ophthalmology for the Primary Care Physician; Palay D A, Krachmer J H, eds: Mosby 1997 Solley W A, Kardon R, Thompson HS. Relative Contributions of the Nasal and Temporal Fields in Normal Eyes; Comparison of Visual and Pupillomotor Input. Research at the University of Iowa, Department of Ophthalmology, August May Solley W A, Vitreous Substitutes In: Vitreoretinal Surgery, Anand, R. editor (in press) CLINICAL TRIALS 1. Principal Investigator: B7A-MC-MBDL: Eli Lilly Reduction of the Occurrence of Centerthreatening Diabetic Macular Edema 2. Principal Investigator: Allergan, A Six-month Phase 3, Multicenter, Masked, Randomized, Sham- Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 ug and 350 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System ) in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion. 3. Principal Investigator: Genentech Focus Protocol FVF2428g: A Phase I/II, single-masked, multicenter study of the safety, tolerability, and efficacy of multiple-dose intravitreal injections of rhufab V2 in combination with Verteporfin (Visudyne ) Photodynamic Therapy in subjects with Neovascular age-related Macular Degeneration 4. Principal Investigator: Genentech Protocol FVF 2128G, A Phase I/II Multicenter Dose Escalation Controlled Study of the Safety, Tolerability, and Pharmacokinetics, and the Activity of Multiple Dose Intravitreal Injections of Rhu-FAB V2 in Subjects with Neovascular Age-Related Macular Degeneration; Genentech, San Francisco, CA; 7/2001

4 5. Principal Investigator: The Effects of Infant Formula Supplemented with Long Chain Polyunsaturated Fatty Acids on Visual and Cognitive Development in Term Infants 6. Sub-Investigator: DRCR-2, Intravitreal Triamcinolone for Diabetic Macular Edema 7. Sub-Investigator: ALCON, Administration of Anecortave Acetate for the Treatment of Choroidal Neovascularization 8. Sub-Investigator: A pilot study of Laser Photocoagulation for Diabetic Macular Edema (DRCR #1a) 9. Sub-Investigator: The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study 10. Sub-Investigator: Bausch and Lomb Protocol BLP , A Multicenter, Randomized, Double-Masked Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide (0.5 or 2.0 mg) Implant in Patients with Non-infectious Uveitis Affecting the Posterior Segment of the Eye; Bausch and Lomb Pharmaceuticals, Tampa, FL 10/ Sub-Investigator: Control Delivery Systems Protocol CDS FL-002, A Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinlolne (0.6 or 2.1 mg) Implant in Patients with Diabetic Macular Edema; Control Delivery Systems, Inc., Watertown, MA 10/ Sub-Investigator: Control Delivery Systems Ophthalmic Consultant: TAP Pharmaceutical Products, Inc. Protocol M Investigational Drug Study for Overactive Bladder, June Ophthalmic Consultant: TAP Pharmaceutical Products, Inc. Protocol TAK Investigational Drug Study for Overactive Bladder, 52 Week Extension Study, September Principal Investigator: MacuSight DR : Clinical Study to Assess the Safety and Tolerability of MS-R001 in patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy. Closed. 16. Sub-Investigator: Age-Related Eye Disease Study 2 (AREDS 2), Trial of Lutein, Zeaxanthin, and Omega-3 Long-Chain Polyunsaturated Fatty Acids in Age-Related Macular Degeneration. Ongoing. 17. Sub-Investigator: RAP: Ranibizumab and Reduced Fluence Photodynamic Therapy for Choroidal Neovascularization in Age-Related Macular Degeneration. Closed. 18. Sub-Investigator: Sirion: A Phase II Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety of Efficacy of Fenretinide in the Treatment of Geographic Atrophy in subjects with Age-Related Macular Degeneration. Closed.

5 19. Sub-Investigator: ALCON GAP: The Natural History of Geographic Atrophy Progression (GAP) Secondary to Age-Related Macular Degeneration. Closed. 20. Sub-Investigator: Allergan : Assess the Safety and Efficacy of 700ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in combination with Laser Photocoagulation Compared with Laser Photocoagulation alone in the Treatment of Subjects with Diffuse Diabetic Macular Edema (DME). Closed. 21. Sub-Investigator: SCORE: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edeam: One for Central Reinal Vein Occlusion and one for Branc Retinal Vein Occlusion. Closed. 22. Sub-Investigator: Allergan : An 8-week, Multi-Center, Masked, Randomized Trial (with an 18-week masked extension) to Assess the Safety and Efficacy of 700ug and 350 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System compared with Sham DEX PS DDS Applicator System in the Treatment of Non-Infectious Ocular Inflammation of the Posterior Segment in Patients with Intermediate or Posterior Uveitis. Closed. 23. Sub-Investigator: Allergan D: A 12-month, Open-Label Trial to Assess the Safety of 50ug Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in Patients with Diabetic Macular Ischemia. Closed. 24. Sub-Investigator: DRCR: Protocol B: Diabetic Retinopathy Clinical Research Network A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema. Closed. 25. Sub-Investigator: DRCR: Protocol H: A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) Closed. 26. Sub-Investigator: DRCR: Protocol J: Diabetic Retinopathy Clinical Research Network Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. Closed. 27. Sub-Investigator: LUX 21101: A Double-Masked, Placebo-Controlled, Multi-Center, Dose Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Uveitis. Closed. 28. Sub-Investigator: LUX 21102: A Double-Masked, Placebo-Controlled, Multi-Center, Dose Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Quiescent Sight Threatening, Non-Infectious Uveitis. Closed. 29. Sub-Investigator: Racial: A Multi-Center, Ranodmized, Single-Masked Study Comparing Reduced Fluence Visydyne-Lucentis Combination Therapies and Lucentis Mono-therapy in Subjects with CNV Secondary to AMD. Closed. 30. Sub-Investigator: READ 3: JDRF Multi-Center Clinical Investigation of Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 with High Dose. Ongoing.

6 LECTURES 31. Sub-Investigator: Alcon: C (GATE): The Safety and Efficacy of AL-8309B Ophthalmic Solution for the treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration. 32. Sub-Investigator: AGN : Single-Dose Study of the Safety and Efficacy of AGN in Patients with Exudative Age-Related Macular Degeneration. 33. Sub-Investigator: LUX : A Double-Masked, Placebo Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Non- Infectious Intermediate, Posterior or Pan-Uveitis. Ongoing. 34. Sub-Investigator: AGN : A Multi-Center, Open-Label, Randomized Study comparing the Efficacy and Safety of 700ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in patients with Diabetic Macular Edema. 35. Sub-Investigator: ideal : A Randomized, Multi-Center, Phase II Study of the Safety, Tolerability and Bioactivity of repeated Intravitreal Injection(s) ico-007 as Monotherapy or in combination with Ranibizumab or Laser Photocoagulation in the treatment of Diabetic Macular Edema with Involvement of the Foveal Center. 36. Sub-Investigator: TRA-OZAB : The Effect of Ozurdex (Dexamethasone Intravitreal Implant) 0.7mg on Efficacy of Bevacizumab Therapy for Non-Ischemic Retinal Vein Occlusion. 37. Sub-Investigator: Regeneron VGFTe-AMD-1124: An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in patients with Neovascular Age-Related Macular Degeneration. Quacking and Having Feathers Does Not Always Make a Duck: Maculopathy Misdiagnosis, Vitreoretinal Disease Update, Presbyterian Hospital, Dallas, TX 3/24/2013 Vitreoretinal Surgery in the ASC, Invited Lecture at ASRS, 8/20/2011 Surgical Potpourri A Video-Tour-de-Force, Vitreoretinal Disease Update, Presbyterian Hospital, Dallas, TX 5/15/2011 Macular Disorders: I Know It s the Macula but I Don t Know What It Is, Vitreoretinal Disease Update, Presbyterian Hospital, Dallas, TX 2010 Vitreoretinal Surgery 2010 The Confluence of Technology. Alcon National Sales Conference, Irving, TX 2010 Size Matters: 25guage vs. 23guage vs. 20guage Vitrectomies, Vitreoretinal Disease Update, Presbyterian Hospital, Dallas, TX 2009 Making the Switch to EMR, Club-Vit Annual Meeting, 2008

7 Mysterious Maculas- Diagnosis and Treatment, Vitreoretinal Disease Update, Presbyterian Hospital, Dallas, TX 5/18/2008 Diabetic Retinopathy What s New and Exciting, Vitreoretinal Disease Update, Presbyterian Hospital, Dallas, TX 5/20/2007 Macular Spots A Review of Commonly-Seen Maculopathies, Vitreoretinal Disease Update, Presbyterian Hospital, Dallas, TX 4/30/2006 Diabetic Macular Edema: Assessment, Management and Treatment, Vitreoretinal Disease Update, Presbyterian Hospital, Dallas, TX 5/22/2005 Macular Degeneration 2004, ASORN Lecture, Fort Worth, TX 7/2004 OCT 202- Identification and Treatment of Macular Pathology in the OCT Era, Vitreoretinal Disease Update, Presbyterian Hospital, Dallas, TX 5/2004 Diabetic Retinopathy When To Get Them Out of Your Office, Vitreoretinal Disease Update, Presbyterian Hospital, Dallas, TX 5/2003 Vascular Occlusive Disease of the Retina, ASORN Lecture, Dallas, TX 6/2003 Vascular Occlusive Disease of the Retina: Surgical, Spring Ophthalmology Symposium, Presbyterian Hospital of Dallas, Dallas, Texas, 4/2003 Vascular Occlusive Disease of the Retina: Medical, Spring Ophthalmology Symposium, Presbyterian Hospital of Dallas, Dallas, Texas, 4/2003 Idiopathic Macular Holes, Vitroretinal Disease Update, Presbyterian Hospital of Dallas, Dallas, Texas, 5/2001 Retina Look-Alikes, Vitroretinal Disease Update, Presbyterian Hospital of Dallas, Dallas, Texas, 5/2001 Age-Related Eye Disease, Arlington Memorial Hospital Community Fair, Arlington, Texas, 2/2000 Retinal Detachment and Diabetic Retinopathy: Evaluation and Treatment, Tarrant County Optometric Society Annual Meeting, Fort Worth, Texas, 2000 Ocular Trauma, Vitroretinal Disease Update, Presbyterian Hospital of Dallas, Dallas, Texas, 10/1999 Signed: Wayne A. Solley, M.D. Date: Updated 4/9/2013

Darren J. Bell, M.D. Texas A&M University College of Medicine College Station, Texas Doctor of Medicine

Darren J. Bell, M.D. Texas A&M University College of Medicine College Station, Texas Doctor of Medicine Darren J. Bell, M.D. Education Texas A&M University College of Medicine College Station, Texas Doctor of Medicine 1997-2001 Texas A&M University College Station, Texas Bachelor of Science, Biomedical Engineering